FDA Approves LEUPROLIDE ACETATE — Meitheal Pharmaceuticals Inc

# FDA Approves Generic Leuprolide Acetate for Meitheal Pharmaceuticals Meitheal Pharmaceuticals Inc received FDA approval for its generic leuprolide acetate injection (ANDA075471), a subcutaneous formulation that addresses a significant market opportunity in the hormone therapy and oncology treatment segments. The approval enables Meitheal to compete directly with brand-name leuprolide products, potentially offering cost savings to healthcare providers and payers while expanding the company's footprint in the specialty pharmaceuticals market.